Michael B. Major, PhD

michael major

Assistant Professor
Molecular Rationale for WNT Inhibitor Therapy in B-Cell Lymphoma
UNC Lineberger

The FOXP1 protein is overexpressed in B-cell lymphomas, and patients with high FOXP1 levels often resist therapy and are given a poor prognosis. We discovered that FOXP1 activates the WNT signaling pathway. We will determine whether WNT inhibitors currently in clinical trails for other cancers will benefit lymphoma patients.